PDGFRα: a new therapeutic target in the treatment of hepatocellular carcinoma? (Q59150841)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19335066%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

review article

1 reference

title

PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19335066%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19335066%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Abdul M Oseini

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19335066%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

language of work or name

English

0 references

publication date

1 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19335066%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19335066%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19335066%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19335066%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

443-454

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19335066%20AND%20SRC:MED&resulttype=core&format=json

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Sorafenib in liver cancer--just the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Treatment options for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Emerging drugs for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

The PDGF family: four gene products form five dimeric isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

A structural superfamily of growth factors containing a cystine knot motif

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Role of platelet-derived growth factors in physiology and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFD genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

New members of the platelet-derived growth factor family of mitogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

PDGF receptors as cancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Autocrine PDGFR signaling promotes mammary cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Targeting vessels to treat hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Platelet-derived growth factor BB stimulates vasculogenesis of embryonic stem cell-derived endothelial cells by calcium-mediated generation of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Vascular endothelial growth factor can signal through platelet-derived growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Platelet-Derived Growth Factor is AngiogenicIn Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

PDGF-D is a potent transforming and angiogenic growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Overexpression of PDGF-A in the lung epithelium of transgenic mice produces a lethal phenotype associated with hyperplasia of mesenchymal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Involvement of platelet-derived growth factor in disease: development of specific antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Oncogenic derivatives of platelet-derived growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Receptor tyrosine kinases as targets for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

CD117 (c-kit) expression in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

PDGF receptors as targets in tumor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Phase II study of imatinib in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Syndecans: multifunctional cell-surface co-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Functions of cell surface heparan sulfate proteoglycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

HSulf-1 inhibits angiogenesis and tumorigenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220902719233

10.1517/14728220902719233

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19335066%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference